Glenmark wins FDA nod for Phase II study of nebulized tiotropium bromide

Glenmark Pharmaceuticals said today that the FDA approved its Investigational New Drug application for a Phase II study of its nebulized tiotropium bromide.

The Mahwah, N.J.-based company plans to enroll 155 patients with mild to moderate chronic obstructive pulmonary disease and evaluate its GSP 304 formulation as a daily maintenance treatment for bronchospasm.

Get the full story at our sister site, Drug Delivery Business News.

The post Glenmark wins FDA nod for Phase II study of nebulized tiotropium bromide appeared first on MassDevice.

from MassDevice http://ift.tt/2mZxD9b